LLY vs PAVM

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

PAVmed Inc. (PAVM) remains a highly speculative, high-risk, high-reward investment, yet its financial runway has materially improved since the last analysis. The completion of a $30M Series D preferred stock and $15M senior secured note financing provides a crucial $45M capital infusion, significantly alleviating the immediate cash burn and precarious financial position that previously justified a...